To screen for the inactivation of SDHB across CNS tumors, we performed SDHB immunohistochemistry using TMA blocks including 17 cases of glioblastoma, 7 of astrocytoma, 9 of oligodendroglioma, 9 of ependymoma, 10 of meningioma, 6 of hemangiopericytoma, 7 of central neurocytoma, 12 of PA, 5 of craniopharyngioma, 3 of schwannoma, and 3 of hemangioblastoma. Here, SDHB is linked to craniopharyngioma.